Published in Oncology on May 16, 2011
miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance. Cancer Res (2013) 1.29
The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle (2013) 1.08
Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics (2012) 1.04
DNA methylation profiles of airway epithelial cells and PBMCs from healthy, atopic and asthmatic children. PLoS One (2012) 1.04
Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget (2014) 0.98
Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers. Epigenetics (2013) 0.96
Genome-wide DNA methylation profiling of cell-free serum DNA in esophageal adenocarcinoma and Barrett esophagus. Neoplasia (2012) 0.88
Integrative genomic analysis identifies epigenetic marks that mediate genetic risk for epithelial ovarian cancer. BMC Med Genomics (2014) 0.86
DNA methylation changes in epithelial ovarian cancer histotypes. Genomics (2015) 0.80
BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism. Oncotarget (2015) 0.79
Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice. J Cancer (2016) 0.78
Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary. J Cancer Res Clin Oncol (2012) 0.77
Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells. Cell Cycle (2017) 0.75
Molecular Subtyping of Serous Ovarian Cancer Based on Multi-omics Data. Sci Rep (2016) 0.75
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol (2009) 6.56
Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol (2014) 6.28
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. Aging Cell (2009) 2.84
Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol (2013) 2.69
TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology (2003) 2.58
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2009) 2.47
Aging of blood can be tracked by DNA methylation changes at just three CpG sites. Genome Biol (2014) 2.40
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res (2007) 2.21
GM foods and the misperception of risk perception. Risk Anal (2004) 2.20
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia (2004) 2.08
Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet (2012) 2.07
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood (2008) 1.97
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene (2005) 1.89
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer. Breast Cancer Res Treat (2007) 1.85
SNPs in ultraconserved elements and familial breast cancer risk. Carcinogenesis (2008) 1.84
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene (2005) 1.80
One-step nucleic acid amplification-a molecular method for the detection of lymph node metastases in breast cancer patients; results of the German study group. Virchows Arch (2008) 1.75
Human adult germline stem cells in question. Nature (2010) 1.74
Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol (2014) 1.69
Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat Dis Int (2007) 1.67
The human retinoblastoma gene is imprinted. PLoS Genet (2009) 1.63
Quantitative cross-validation and content analysis of the 450k DNA methylation array from Illumina, Inc. BMC Res Notes (2012) 1.59
Replicative senescence of mesenchymal stem cells causes DNA-methylation changes which correlate with repressive histone marks. Aging (Albany NY) (2011) 1.58
Endoscopic treatment of arachnoid cysts: a detailed account of surgical techniques and results. Neurosurgery (2010) 1.57
Modeling of asymmetric cell division in hematopoietic stem cells--regulation of self-renewal is essential for efficient repopulation. Stem Cells Dev (2009) 1.57
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
Epigenetic-aging-signature to determine age in different tissues. Aging (Albany NY) (2011) 1.55
DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab (2013) 1.55
Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett (2008) 1.54
Technical aids in the diagnosis of brain death: a comparison of SEP, AEP, EEG, TCD and CT angiography. Dtsch Arztebl Int (2012) 1.53
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
Specific age-associated DNA methylation changes in human dermal fibroblasts. PLoS One (2011) 1.51
Limited relevance of the CHEK2 gene in hereditary breast cancer. Int J Cancer (2004) 1.49
A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One (2009) 1.48
Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. Hum Mutat (2010) 1.45
Endoscopic transventricular third ventriculostomy through the lamina terminalis. J Neurosurg (2010) 1.44
Calcification or dedifferentiation: requirement to lock mesenchymal stem cells in a desired differentiation stage. J Cell Physiol (2009) 1.42
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2010) 1.41
Reduced metastasis-suppressor gene mRNA-expression in breast cancer brain metastases. J Cancer Res Clin Oncol (2004) 1.40
A variant affecting miRNAs binding in the circadian gene Neuronal PAS domain protein 2 (NPAS2) is not associated with breast cancer risk. Breast Cancer Res Treat (2010) 1.38
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res (2012) 1.38
Activated Cdc42-associated kinase 1 is a component of EGF receptor signaling complex and regulates EGF receptor degradation. Mol Biol Cell (2006) 1.37
Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int J Cancer (2009) 1.37
Mesenchymal stem cells and cardiac repair. J Cell Mol Med (2008) 1.37
Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J Cell Mol Med (2008) 1.33
Pluripotent stem cells escape from senescence-associated DNA methylation changes. Genome Res (2012) 1.32
A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. Breast Cancer Res Treat (2009) 1.30
Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer (2011) 1.30
Characterization of the human GARP (Golgi associated retrograde protein) complex. Exp Cell Res (2005) 1.30
Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer. Hum Mutat (2011) 1.29
Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer (2013) 1.26
Co-culture with mesenchymal stromal cells increases proliferation and maintenance of haematopoietic progenitor cells. J Cell Mol Med (2009) 1.25
Calcium activates Nedd4 E3 ubiquitin ligases by releasing the C2 domain-mediated auto-inhibition. J Biol Chem (2010) 1.25
Global DNA methylation in fetal human germ cells and germ cell tumours: association with differentiation and cisplatin resistance. J Pathol (2010) 1.24
Endoscopic third ventriculostomy in infants of less than 1 year of age: which factors influence the outcome? Childs Nerv Syst (2004) 1.23
Impact of individual platelet lysates on isolation and growth of human mesenchymal stromal cells. Cytotherapy (2010) 1.23
Modulation of calcium-activated potassium channels induces cardiogenesis of pluripotent stem cells and enrichment of pacemaker-like cells. Circulation (2010) 1.22
Monitoring of cellular senescence by DNA-methylation at specific CpG sites. Aging Cell (2012) 1.22
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res (2011) 1.22
Donor age of human platelet lysate affects proliferation and differentiation of mesenchymal stem cells. PLoS One (2012) 1.18
MicroRNAs are shaping the hematopoietic landscape. Haematologica (2011) 1.17
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2012) 1.17
Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density. Cell Transplant (2011) 1.17
Population dynamics of mesenchymal stromal cells during culture expansion. Cytotherapy (2011) 1.16
Bcl-B expression in human epithelial and nonepithelial malignancies. Clin Cancer Res (2008) 1.16
N-cadherin is expressed on human hematopoietic progenitor cells and mediates interaction with human mesenchymal stromal cells. Stem Cell Res (2010) 1.16
Replicative senescence-associated gene expression changes in mesenchymal stromal cells are similar under different culture conditions. Haematologica (2010) 1.14
Stem cells and ageing. The potential of stem cells to overcome age-related deteriorations of the body in regenerative medicine. EMBO Rep (2005) 1.13
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Satellite-based terrestrial production efficiency modeling. Carbon Balance Manag (2009) 1.11
Primary pulmonary choriocarcinoma: case report and review of the literature. Gynecol Obstet Invest (2012) 1.11
Parthenogenetic stem cells for tissue-engineered heart repair. J Clin Invest (2013) 1.11
Tumor-associated alterations in caspase-14 expression in epithelial malignancies. Clin Cancer Res (2005) 1.11
Two-photon absorption and self-phase modulation measurements with shaped femtosecond laser pulses. Opt Lett (2005) 1.10
Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis. Clin Exp Metastasis (2007) 1.10
A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. Carcinogenesis (2008) 1.09
Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Breast Cancer Res Treat (2014) 1.08
Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma--epigenetic downregulation of caspases. Int J Cancer (2008) 1.08
Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. Carcinogenesis (2006) 1.07
Induced pluripotent mesenchymal stromal cell clones retain donor-derived differences in DNA methylation profiles. Mol Ther (2012) 1.07
Examination of apoptosis signaling in pancreatic cancer by computational signal transduction analysis. PLoS One (2010) 1.07